Safety and efficacy of a mutagen-attenuated Rift valley fever virus vaccine in cattle

J. C. Morrill, C. A. Mebus, C. J. Peters

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Objective - To examine safety and efficacy of a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) in cattle. Animals - 38 pregnant cows, 14 steers, and 10 lactating dairy cows. Procedure-Pregnant cows in their third, fifth, or eighth month of gestation were vaccinated (1 ml of RVF MP-12 containing 5 log10 plaque-forming units [PFU] of virus) and were monitored daily through parturition for signs of disease, viremia, and immunologic response. Additionally, 10 vaccinated pregnant cows were challenge inoculated with virulent RVFV at post-vaccination day (PVD) 30 and were monitored daily for untoward effects. Ten unvaccinated pregnant cows also were challenge inoculated with virulent RVFV and served as challenge controls. Vaccinated lactating dairy cows were monitored for viremia and virus shedding in the milk through PVD 14. Yearling steers were vaccinated to assess their immunologic response to various doses of vaccine and were challenge inoculated with virulent RVFV at PVD 28 to assess protection. Results - 10 of 38 (26.3%) cows vaccinated during pregnancy developed transient postvaccination viremia titer ≤ 2.5 log10 PFU/ml of serum. All vaccinated cows delivered live, healthy calves that were RVFV seronegative at birth, but which quickly acquired colostral antibodies. Vaccinated cows and their fetuses were protected when challenge exposed with virulent RVFV at PVD 30, whereas unvaccinated pregnant cows inoculated with RVFV became febrile and viremic, and aborted. Vaccine virus was unsuccessfully sought from milk of lactating dairy cows after vaccination, suggesting that shedding of vaccine virus through milk should not be a concern. Steers, inoculated with tenfold escalating vaccine doses, beginning with 1.0 log10 PFU, were protected against virulent RVFV challenge exposure. Conclusions - RVF MP-12 may be safe and efficacious for use in pregnant or lactating bovids, and a minimal dose of vaccine may provide suitable protection against viremia.

Original languageEnglish (US)
Pages (from-to)1104-1109
Number of pages6
JournalAmerican Journal of Veterinary Research
Volume58
Issue number10
StatePublished - Oct 1997
Externally publishedYes

Fingerprint

Rift Valley fever virus
Mutagens
Vaccines
vaccines
Safety
cows
Viremia
cattle
viremia
Vaccination
vaccination
Virus Shedding
Milk
dairy cows
milk
viruses
dosage
Parturition
pregnancy
Viruses

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Safety and efficacy of a mutagen-attenuated Rift valley fever virus vaccine in cattle. / Morrill, J. C.; Mebus, C. A.; Peters, C. J.

In: American Journal of Veterinary Research, Vol. 58, No. 10, 10.1997, p. 1104-1109.

Research output: Contribution to journalArticle

Morrill, J. C. ; Mebus, C. A. ; Peters, C. J. / Safety and efficacy of a mutagen-attenuated Rift valley fever virus vaccine in cattle. In: American Journal of Veterinary Research. 1997 ; Vol. 58, No. 10. pp. 1104-1109.
@article{46e8549c5fd04edeb76130f47011625b,
title = "Safety and efficacy of a mutagen-attenuated Rift valley fever virus vaccine in cattle",
abstract = "Objective - To examine safety and efficacy of a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) in cattle. Animals - 38 pregnant cows, 14 steers, and 10 lactating dairy cows. Procedure-Pregnant cows in their third, fifth, or eighth month of gestation were vaccinated (1 ml of RVF MP-12 containing 5 log10 plaque-forming units [PFU] of virus) and were monitored daily through parturition for signs of disease, viremia, and immunologic response. Additionally, 10 vaccinated pregnant cows were challenge inoculated with virulent RVFV at post-vaccination day (PVD) 30 and were monitored daily for untoward effects. Ten unvaccinated pregnant cows also were challenge inoculated with virulent RVFV and served as challenge controls. Vaccinated lactating dairy cows were monitored for viremia and virus shedding in the milk through PVD 14. Yearling steers were vaccinated to assess their immunologic response to various doses of vaccine and were challenge inoculated with virulent RVFV at PVD 28 to assess protection. Results - 10 of 38 (26.3{\%}) cows vaccinated during pregnancy developed transient postvaccination viremia titer ≤ 2.5 log10 PFU/ml of serum. All vaccinated cows delivered live, healthy calves that were RVFV seronegative at birth, but which quickly acquired colostral antibodies. Vaccinated cows and their fetuses were protected when challenge exposed with virulent RVFV at PVD 30, whereas unvaccinated pregnant cows inoculated with RVFV became febrile and viremic, and aborted. Vaccine virus was unsuccessfully sought from milk of lactating dairy cows after vaccination, suggesting that shedding of vaccine virus through milk should not be a concern. Steers, inoculated with tenfold escalating vaccine doses, beginning with 1.0 log10 PFU, were protected against virulent RVFV challenge exposure. Conclusions - RVF MP-12 may be safe and efficacious for use in pregnant or lactating bovids, and a minimal dose of vaccine may provide suitable protection against viremia.",
author = "Morrill, {J. C.} and Mebus, {C. A.} and Peters, {C. J.}",
year = "1997",
month = "10",
language = "English (US)",
volume = "58",
pages = "1104--1109",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "10",

}

TY - JOUR

T1 - Safety and efficacy of a mutagen-attenuated Rift valley fever virus vaccine in cattle

AU - Morrill, J. C.

AU - Mebus, C. A.

AU - Peters, C. J.

PY - 1997/10

Y1 - 1997/10

N2 - Objective - To examine safety and efficacy of a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) in cattle. Animals - 38 pregnant cows, 14 steers, and 10 lactating dairy cows. Procedure-Pregnant cows in their third, fifth, or eighth month of gestation were vaccinated (1 ml of RVF MP-12 containing 5 log10 plaque-forming units [PFU] of virus) and were monitored daily through parturition for signs of disease, viremia, and immunologic response. Additionally, 10 vaccinated pregnant cows were challenge inoculated with virulent RVFV at post-vaccination day (PVD) 30 and were monitored daily for untoward effects. Ten unvaccinated pregnant cows also were challenge inoculated with virulent RVFV and served as challenge controls. Vaccinated lactating dairy cows were monitored for viremia and virus shedding in the milk through PVD 14. Yearling steers were vaccinated to assess their immunologic response to various doses of vaccine and were challenge inoculated with virulent RVFV at PVD 28 to assess protection. Results - 10 of 38 (26.3%) cows vaccinated during pregnancy developed transient postvaccination viremia titer ≤ 2.5 log10 PFU/ml of serum. All vaccinated cows delivered live, healthy calves that were RVFV seronegative at birth, but which quickly acquired colostral antibodies. Vaccinated cows and their fetuses were protected when challenge exposed with virulent RVFV at PVD 30, whereas unvaccinated pregnant cows inoculated with RVFV became febrile and viremic, and aborted. Vaccine virus was unsuccessfully sought from milk of lactating dairy cows after vaccination, suggesting that shedding of vaccine virus through milk should not be a concern. Steers, inoculated with tenfold escalating vaccine doses, beginning with 1.0 log10 PFU, were protected against virulent RVFV challenge exposure. Conclusions - RVF MP-12 may be safe and efficacious for use in pregnant or lactating bovids, and a minimal dose of vaccine may provide suitable protection against viremia.

AB - Objective - To examine safety and efficacy of a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) in cattle. Animals - 38 pregnant cows, 14 steers, and 10 lactating dairy cows. Procedure-Pregnant cows in their third, fifth, or eighth month of gestation were vaccinated (1 ml of RVF MP-12 containing 5 log10 plaque-forming units [PFU] of virus) and were monitored daily through parturition for signs of disease, viremia, and immunologic response. Additionally, 10 vaccinated pregnant cows were challenge inoculated with virulent RVFV at post-vaccination day (PVD) 30 and were monitored daily for untoward effects. Ten unvaccinated pregnant cows also were challenge inoculated with virulent RVFV and served as challenge controls. Vaccinated lactating dairy cows were monitored for viremia and virus shedding in the milk through PVD 14. Yearling steers were vaccinated to assess their immunologic response to various doses of vaccine and were challenge inoculated with virulent RVFV at PVD 28 to assess protection. Results - 10 of 38 (26.3%) cows vaccinated during pregnancy developed transient postvaccination viremia titer ≤ 2.5 log10 PFU/ml of serum. All vaccinated cows delivered live, healthy calves that were RVFV seronegative at birth, but which quickly acquired colostral antibodies. Vaccinated cows and their fetuses were protected when challenge exposed with virulent RVFV at PVD 30, whereas unvaccinated pregnant cows inoculated with RVFV became febrile and viremic, and aborted. Vaccine virus was unsuccessfully sought from milk of lactating dairy cows after vaccination, suggesting that shedding of vaccine virus through milk should not be a concern. Steers, inoculated with tenfold escalating vaccine doses, beginning with 1.0 log10 PFU, were protected against virulent RVFV challenge exposure. Conclusions - RVF MP-12 may be safe and efficacious for use in pregnant or lactating bovids, and a minimal dose of vaccine may provide suitable protection against viremia.

UR - http://www.scopus.com/inward/record.url?scp=0030874805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030874805&partnerID=8YFLogxK

M3 - Article

C2 - 9328662

AN - SCOPUS:0030874805

VL - 58

SP - 1104

EP - 1109

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 10

ER -